⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31505845 | 1.00 | — | — | |
| SCHEMBL13243216 | 1.00 | — | — | |
| SCHEMBL25902381 | 0.91 | THRB (0.40) | — | |
| SCHEMBL8652027 | 0.87 | THRB (0.42) | — | |
| SCHEMBL19257468 | 0.85 | MAPT (0.40) | — | |
| SCHEMBL4963433 | 0.84 | — | — | |
| SCHEMBL4963430 | 0.84 | — | — | |
| SCHEMBL11211264 | 0.84 | THRB (0.39) | — | |
| SCHEMBL1771125 | 0.82 | MAPT (0.33) | — | |
| SCHEMBL19257465 | 0.81 | THRB (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066667-B2 | Organic compositions to treat APOC3-related diseases | Arrowhead Pharmaceuticals, Inc. (US) | 2021-07-20 | — | — | US | claimed |
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2021-05-18 | — | — | US | claimed |
| CN-105792832-B | Organic compounds for the treatment of hepatitis B virus | 诺华股份有限公司 | 2021-03-23 | — | — | CN | claimed |
| EP-3736334-A1 | RNAI COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | Arrowhead Pharmaceuticals, Inc. (US) | 2020-11-11 | — | — | EP | claimed |
| EP-3722277-A2 | 3'END CAPS FOR RNA-INTERFERRING AGENTS FOR USE IN RNA | Novartis AG (CH) | 2020-10-14 | — | — | EP | claimed |
| EP-3169784-B1 | RNAI COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | ARROWHEAD PHARMACEUTICALS INC (US) | 2020-06-10 | — | — | EP | claimed |
| EP-3052464-B1 | 3'END CAPS FOR RNA-INTERFERRING AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2020-04-15 | — | — | EP | claimed |
| US-10519446-B2 | Organic compounds to treat hepatitis B virus | NOVARTIS AG (CH) | 2019-12-31 | — | — | US | claimed |
| US-20190233817-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-01 | — | — | US | claimed |
| US-10240153-B2 | Organic compositions to treat APOC3-related diseases | Arrowhead Pharmaceuticals, Inc. (US) | 2019-03-26 | — | — | US | claimed |
| EP-3052464-A2 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | Novartis AG (CH) | 2016-08-10 | — | — | EP | claimed |
| EP-3052107-A2 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | Novartis AG (CH) | 2016-08-10 | — | — | EP | claimed |
| EP-3052627-A2 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | Novartis AG (CH) | 2016-08-10 | — | — | EP | claimed |
| US-20160215288-A1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-07-28 | — | — | US | claimed |
| WO-2016011123-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | ARROWHEAD RESEARCH CORPORATION (US) | 2016-01-21 | — | — | WO | claimed |
| WO-2015051045-A2 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | claimed |
| WO-2015051366-A2 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | claimed |
| WO-2015050871-A2 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | claimed |
| WO-2015051135-A2 | ORGANIC COMPOSITIONS TO TREAT HEPCIDIN-RELATED DISEASES | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | claimed |
| WO-2015051044-A2 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | claimed |